InvestorsHub Logo
icon url

DewDropStew

02/17/21 3:35 PM

#105111 RE: trading.jeff #105104

USRM target of .019 after release of court decision.

Once the court chatter is gone... they have effectively Zero PR and price is expected to decline while other stem cell clinics take advantage of the new ruling, which that they are already operating in.

USRMs court case will promote the competition clinics more so than USRM due the company’s horrible track record of law suits.

Let the more diligent practitioners use stem cells for patients in a non-public entity.

.019 is still in play.